Antibe Therapeutics
| File:Antibe Therapeutics logo.jpg | |
| Company type | Publicly traded corporation |
|---|---|
| TSX-V: ATE OTCQX: ATBPF | |
| Industry | Pharmaceuticals |
| Founded | 1 January 2010  |
| Headquarters | Toronto , Canada |
Key people | Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Science Officer |
| Website | www |
Antibe Therapeutics is a Toronto-based pharmaceutical company that develops inflammation-reducing drugs based on gaseous mediator technology.[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. In 2015, Antibe acquired Citagenix, a developer and distributor involved in regenerative medicine.[2]
Products
The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[3] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[4] Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to rheumatoid arthritis and other diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.[5]
In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[6] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[7] In mid-January 2015, the company announced that clinical trials for its first drug were being suspended due to safety concerns; clinical trials were restarted in March 2015.[8]
Antibe's products have not yet been approved by the US Food and Drug Administration.
People
Antibe's science advisory board:[9]
- Andre G. Buret, Professor, University of Calgary, Canada
- Giuseppe Cirino, PhD, Professor, University of Naples, Italy
- Gilberto de Nucci, MD, PhD, Professor, University of Sao Paulo, Brazil
- Peter B. Ernst, DVM, PhD, Professor, UCSD, San Diego, USA
- Derek Gilroy, PhD, Professor, University College, London, UK
- Richard H. Hunt, MD, Emeritus Professor, McMaster University, Canada
- Louis Ignarro, PhD Professor, UCLA, Los Angeles, USA - 1998 Nobel Prize Laureate in Medicine
- Jane A. Mitchell, PhD, Professor, Imperial College, London, UK
- Mauro Perretti, PhD, Professor, William Harvey Research Institute,[10] London, UK
- Daniel K. Podolsky, MD, President, University of Texas Southwestern Medical Center, USA
- William Sessa, PhD, Professor, Yale University, USA
- Philip M. Sherman, MD, Professor, University of Toronto, Canada
Antibe’s board of directors:[11]
- Chair - Walt Macnee, Vice Chair, MasterCard International[12]
- Roderick Flower, Professor, Barts and The London School of Medicine and Dentistry
- Dan Legault, CEO, Antibe Therapeutics
- Samira Sakhia, CFO, Paladin Labs[13]
- John L. Wallace, Chief Science Officer, Antibe Therapeutics
References
- ^ http://www.antibethera.com
- ^ http://www.bloomberg.com/research/stocks/news/article.asp?docKey=600-201602021810BIZWIRE_USPRX____BW6697-1&ex=true&ticker=MNK
- ^ "Archived copy". Archived from the original on 2014-02-02. Retrieved 2014-02-12.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ "Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide". Expert Opin Ther Pat. 19 (5): 663–82. May 2009. doi:10.1517/13543770902858824. PMID 19441940.
- ^ British Journal of Pharmacology "Archived copy" (PDF). Archived from the original (PDF) on 2014-03-05. Retrieved 2014-02-03.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ http://online.wsj.com/article/PR-CO-20140505-901386.html
- ^ http://www.marketwatch.com/story/antibe-therapeutics-announces-first-human-dose-of-atb-346-in-phase-i-clinical-trial-2014-06-26
- ^ http://www.antibethera.com/s/PressReleases.asp?ReportID=699894&_Type=Press-Releases&_Title=ANTIBE-THERAPEUTICS-PROVIDES-AN-UPDATE-ON-ITS-DATA-REVIEW-AND-CORPORATE-STR...
- ^ "Archived copy". Archived from the original on 2014-02-02. Retrieved 2014-02-12.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ http://www.whri.qmul.ac.uk/
- ^ http://antibethera.com/board-of-directors/
- ^ http://investorrelations.mastercardintl.com/phoenix.zhtml?c=148835&p=irol-govBio&ID=144740
- ^ "Archived copy". Archived from the original on 2014-05-22. Retrieved 2014-05-22.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link)